BioAge Labs, Inc. (BIOA) NASDAQ
16.82
-0.0398(-0.24%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
16.82
-0.0398(-0.24%)
Currency In USD
| Previous Close | 17.44 |
| Open | 17.18 |
| Day High | 17.31 |
| Day Low | 16.61 |
| 52-Week High | 24 |
| 52-Week Low | 3.67 |
| Volume | 216,833 |
| Average Volume | 535,990 |
| Market Cap | 606.62M |
| PE | -7.53 |
| EPS | -2.24 |
| Moving Average 50 Days | 18.87 |
| Moving Average 200 Days | 11.76 |
| Change | -0.58 |
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 9:30 PM GMT
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
GlobeNewswire Inc.
Jan 22, 2026 3:30 AM GMT
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o
BioAge Announces Proposed Public Offering
GlobeNewswire Inc.
Jan 20, 2026 9:01 PM GMT
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o